Novo Nordisk shares plummet after weight-loss drug's disappointing trial results
Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Novo Nordisk stock plunges on obesity shot trial results
Novo Nordisk (NVO) is falling by over 20% in Friday's pre-market trading after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted in its clinical trial. Yahoo Finance senior health reporter Anjalee Khemlani expands upon this story and compares Novo Nordisk's stock performance with that of GLP-1 drug competitor Eli Lilly (LLY).
Novo Nordisk Stock Eyes Worst Day, Week on Record
Novo Nordisk A/S (NYSE:NVO) stock is down 18.9% to trade at $82.25 at last check, after the pharmaceutical company's weight loss drug CagriSema missed expectations of a late-stage study.
Novo Nordisk: CagriSema Underwhelms In REDEFINE-1 Trial
Shares of Novo Nordisk A/S are down after underwhelming REDEFINE-1 trial results. The results were positive, but underperformed company and market expectations (including my own). The trial's flexible dosing protocol led to fewer patients reaching the highest dose, impacting the overall efficacy results.
PCE Data Lower Than Expected, NVO Falls on New Obesity Drug, AFRM Upgraded
Jenny Horne joins the Futures show with live reaction to the latest PCE inflation data. November rate rose just 0.1% from October, but on an annual basis checked in at 2.4% On the stock front, Novo Nordisk (NVO) slid sharply after disappointing clinical data for its new obesity drug CagriSema.
Novo Nordisk Stock: A Rare Buying Opportunity
As I'm writing these lines, Novo Nordisk A/S stock is down about 16% on the pre-market session after the news came out that CagriSema delivered disappointing trial results. I think this selloff is a rare buying opportunity to buy NVO stock at about fair stock price, judging by the long-term average valuation ratios. The business experienced 22.7% YoY revenue growth in US dollars during Q3 FY2024 and managed to expand its EBIT margin to over 47% (+95 bps QoQ and +161 bps YoY).
Novo Nordisk shares drop after weight loss drug trial disappoints
Novo Nordisk (NYSE:NVO) shares plunged more than 20% before Friday's opening bell after the drugmaker reported results from a late-stage trial of its weight loss drug CagriSema that fell short of expectations. The company reported that patients in the trial achieved weight loss of 22.7% after 68 weeks, below the 25% it had previously guided.
Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight Loss Drug
Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of Ozempic and Wegovy.
Novo Nordisk to explore CagriSema weight-loss potential in new trial
Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it hopes will show greater weight-loss, after posting disappointing late-stage trial data.
Novo Nordisk's new weight-loss drug works better, but not as well as expected
Novo Nordisk's stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
On Friday, Novo Nordisk A/S NVO stock plunged after the company released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.
